Tokyo, Japan and Cambridge, UK, 13 January 2026 - Nxera Pharma Co., Ltd. ('Nxera” or 'the Company”; TSE 4565) notes that ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate TEV-‘408 TEV- ...

LGM Pharma’s Expanded Contract Development and Manufacturing Organization (CDMO) Capabilities Will Enable Customers to Accelerate and Optimize the New Product Pathway from Early Development Through ...

Enter generative AI, which the pharma industry is adopting at a terrific rate. By ingesting and analysing vast biological ...

The engagement will explore the use of cellular fermentation to make key starting materials required for pharmaceutical ...

Partnerships in healthcare have never been more important. Through collaboration, industry specialists are increasingly bringing cutting-edge medical innovations and life-changing treatments to ...

On the 12th (local time), the ‘JP Morgan Healthcare Conference’ opened in San Francisco, U.S. The biggest topic at this ...

Sophie Lamle brings over 20 years of experience in the pharmaceutical industry, leading innovation, clinical development, and strategic transformation. Her appointment will further strengthen LEO ...

Donna Conroy, MS is Founder/CEO of SciMar ONE, Inc. a technology company building AI-based SaaS solutions for the pharmaceutical industry. Investing time and resources is clearly a long-term strategy ...

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing ...

Silo Pharma, Inc., a biopharmaceutical company focused on developing innovative treatments for mental health and chronic pain, announced in a recent letter to shareholders that it expects to submit an ...